Mutant HER2 needs mutant HER3 to be an effective oncogene.
2021
Hanker et al. reveal that co-occurring missense mutations in the human epidermal growth factor receptor 2 (HER2) and its catalytically inactive homolog HER3 synergize to promote oncogenic signaling by the HER2/HER3 complex.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
11
References
0
Citations
NaN
KQI